Mirataz for Cats - 20mg/g - 5g Tube

Description

Mirataz for Cats - 20mg/g - 5g Tube

Mirataz contains the active ingredient, mirtazapine, which addresses reduced appetite and induces significant weight gain in as little as 14 days.

Mirataz is available in a 5g tube with innovative child resistant packaging.

Each dose of 0.1g Mirataz contains: Active substance: Mirtazapine (as hemihydrate) Mirataz is a non-greasy, homogeneous, white to off-white ointment.

Clinical particulars Target species Cats. Indications for use: Mirataz is used for body weight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions (see Pharmacodynamic properties).

Contraindications
Do not use Mirataz in breeding, pregnant or lactating cats. Do not use Mirataz in animals less than 7.5 months of age or less than 2 kg body weight. Do not use Mirataz in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use Mirataz in cats treated with cyproheptadine, tramadol or monoamine oxidase inhibitors (MAOIs) or treated with an MAOI within 14 days prior to treatment with the veterinary medicinal product as there may be an increased risk of serotonin syndrome (see Interactions).

Special warnings for each target species The efficacy of Mirataz has not been established in cats less than 3 years of age. The efficacy and safety of the Mirataz has not been established in cats with severe renal disease and/or neoplasia. Proper diagnosis and treatment of the underlying disease is key to managing weight loss, and treatment options are dependent on the severity of weight loss and underlying disease(s). The management of any chronic disease associated with weight loss should include providing appropriate nutrition and monitoring body weight and appetite.

The therapy with Mirataz should not replace necessary diagnostics and/or treatment regimens needed to manage the underlying disease(s) causing unintended weight loss. The efficacy of Mirataz was only demonstrated with a 14-day administration corresponding to the current recommendations (see Amounts to be administered and administration route). Repetition of the treatment has not been investigated and as such should only be done after benefit-risk balance assessment by the veterinarian. The efficacy and safety of Mirataz has not been established in cats weighing less than 2.1 kg or more than 7.0 kg (see also Amounts to be administered and administration route). Special precautions for use in animals The veterinary medicinal product should not be applied on damaged skin. In the case of hepatic disease, elevated hepatic enzyme levels may be observed. Kidney disease may cause reduced clearance of Mirataz, which may result in higher drug exposure. In these special cases, biochemical hepatic and renal parameters should be regularly monitored during the treatment. The effects of Mirataz on glucose regulation have not been evaluated. In the case of use in cats with diabetes mellitus, glycaemia should be regularly monitored. When used in hypovolemic cats, supportive treatment (fluid therapy) should be implemented. Care should be taken that other animals in the household do not come in contact with the application site until it is dry. Special precautions to be taken by the person administering the veterinary medicinal product to animals The product can be absorbed via the cutaneous or oral route and can cause drowsiness or sedation. Avoid direct contact with the product. Avoid contact with the treated animal for the first 12 hours after each daily application and until the application site is dry. It is therefore recommended to treat the animal with Mirataz in the evening. Treated animals should not be allowed to sleep with owners, especially children and pregnant women during all the period of the treatment. Thoroughly wash hands immediately after administration of the Mirataz or in case of skin contact with the product or the treated cat. Limited data are available on the reproductive toxicity of mirtazapine.

Given that pregnant women are considered a more sensitive population, it is recommended that pregnant women or women trying to conceive should avoid handling Mirataz and avoid contact with treated animals throughout the treatment period. Mirataz may be harmful after ingestion. Do not leave the tube out of its child resistant container except during the application phase. Children must not be present when applying Mirataz to the cat. The tube must be placed in the child resistant container after application, which must be closed immediately. Do not eat, drink or smoke while handling the veterinary medicinal product. The veterinary medicinal product is a skin sensitiser. People with known hypersensitivity to mirtazapine should not handle the veterinary medicinal product.

Mirataz may cause eye and skin irritation. Avoid hand to mouth and hand to eye contact until hands have been thoroughly washed. In the case of contact with eyes, rinse the eyes thoroughly with clean water. In the case of contact with the skin, wash thoroughly with soap and warm water. If skin or eye irritation occurs or in case of accidental ingestion, seek medical advice immediately and show the label to the physician. Adverse reactions

Legal category:
Mirataz is a POM-V (Pet Prescription Required)